ライフサイエンスコーパス: dyspnoea

1 d events (one with hypokalaemia and one with dyspnoea).

2 ore subjective symptoms, such as fatigue and dyspnoea.

3 ion, and arterial blood gases do not measure dyspnoea.

4 and may be a contributing factor to exercise dyspnoea.

5 ich may be a contributing factor to exercise dyspnoea.

6 tent chest pain, palpitations and exertional dyspnoea.

7 atistically significant, effect on decreased dyspnoea.

8 iovascular diseases, referred for exertional dyspnoea.

9 lower asthma severity measured by report of dyspnoea.

10 The most common serious adverse event was dyspnoea (16 [6%] and 15 [5%] in the dovitinib and soraf

11 , and anaemia (5 [5%]), sepsis (2 [2%]), and dyspnoea (2 [2%]) with BAT.

12 I 1.2-2.9]), chronic phlegm (2.0 [1.3-3.0]), dyspnoea (2.3 [1.5-3.5]), asthmatic attacks (3.7 [2.2-6.

13 relation to treatment) were fatigue (3; 6%), dyspnoea (2; 4%), and headache (2; 4%).

14 hypertension (47 [17%]), fatigue (24 [8%]), dyspnoea (21 [7%]), and palmar-plantar erythrodysaesthes

15 12 [2%]), pneumonia (24 [5%] vs five [1%]), dyspnoea (22 [4%] vs nine [2%]), asthenia (27 [5%] vs 17

16 of 292 patients), acneiform rash (31 [11%]), dyspnoea (29 [10%]), and decreased neutrophil count (28

17 tide group vs 14 [3%] in the placebo group), dyspnoea (29 [3%] vs 13 [3%]), and metastases to central

18 ] vs 43 [9%]), fatigue (31 [7%] vs 35 [8%]), dyspnoea (29 [6%] vs ten [2%]), decreased lymphocyte cou

19 vs one [<1%] patient in the placebo group), dyspnoea (29 [8%] vs 24 [13%]), and colitis (24 [6%] vs

20 aminotransferase (240 mg daily) and grade 4 dyspnoea (300 mg daily).

21 s in the placebo group; the most common were dyspnoea (34 [9%] patients in the tremelimumab group vs

22 group vs 25 [8%] in the placebo group]) and dyspnoea (35 [11%] vs 45 [14%]).

23 t (28 [10%]), and with pemetrexed alone were dyspnoea (35 [12%] of 289 patients), decreased neutrophi

24 eater than 2% frequency with tecemotide were dyspnoea (49 [5%] of 1024 patients in the tecemotide gro

25 onse was independently associated with worse dyspnoea (adjusted beta for Modified Medical Research Co

26 naria tenuis with a history of urticaria and dyspnoea after drinking beer and a weak skin reactivity

27 reported symptoms were urticaria, rhinitis, dyspnoea and cough.

28 plain the effects on exacerbation frequency, dyspnoea and exercise capacity.

29 nto two categories: to improve symptoms (ie, dyspnoea and health status) and to decrease future risk

30 All treatments produced improvements in dyspnoea and health-related quality of life; we noted no

31 , tiotropium reduces exacerbation frequency, dyspnoea and improves exercise capacity.

32 ts, aged 18-80 years, with cough, wheeze, or dyspnoea and less than 20% bronchodilator reversibility

33 ohort 2 died due to adverse events, one from dyspnoea and one from multiorgan failure, but neither wa

34 xin was associated with favourable relief of dyspnoea and other clinical outcomes, with acceptable sa

35 diagnoses including non-specific chest pain, dyspnoea and syncope (1368 [6%] deaths), and respiratory

36 han 40, these adverse events included cough, dyspnoea, and abnormal respiration.

37 loped a simplified ADO index (including age, dyspnoea, and airflow obstruction) from the Swiss cohort

38 le functioning, social functioning, fatigue, dyspnoea, and appetite loss on the EORTC QLQ-C30 and pai

39 luding body-mass index, airflow obstruction, dyspnoea, and exercise capacity) was an important contri

40 -life subscales (physical functioning, pain, dyspnoea, and global health status) at any of the assess

41 non-specific symptoms including chest pain, dyspnoea, and palpitations, it often mimics more common

42 f they had life-limiting illness, refractory dyspnoea, and partial pressure of oxygen in arterial blo

43 3 or 4 adverse events were worsening of IPF, dyspnoea, and pneumonia.

44 ncreased alanine aminotransferase, rash, and dyspnoea being the most common.

45 will improve management of problems such as dyspnoea, cachexia, and haemoptysis for patients across

46 ion of adenosine (Ado) to patients can cause dyspnoea, chest discomfort and bronchoconstriction.

47 Typical symptoms include dyspnoea, chest pain, palpitations, and syncope.

48 , had a severe follow-up reaction (involving dyspnoea) compared with 12% initially.

49 tudy, 234 patients with acute heart failure, dyspnoea, congestion on chest radiograph, and increased

50 All patients had dyspnoea, congestion on chest radiograph, increased brai

51 anagement of key symptoms, focusing on pain, dyspnoea, constipation, and anorexia-cachexia syndromes.

52 both the simtuzumab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and

53 hree [4%]), and fatigue, maculopapular rash, dyspnoea, decreased lymphocyte count, and decreased neut

54 Dyspnoea, defined as a sensation of an uncomfortable awa

55 12 of 97 participants had chest tightness or dyspnoea during treatment with lumacaftor alone.

56 eased lipase concentration (12 [9%] of 137), dyspnoea (eight [6%]), and hypertension (seven [5%]).

57 Serelaxin improved the VAS AUC primary dyspnoea endpoint (448 mm x h, 95% CI 120-775; p=0.007)

58 igue (seven [18%] and eight [23%] patients), dyspnoea (five [13%] and seven [20%] patients), and pneu

59 e than one patient in the surgery group were dyspnoea (four [15%] patients), chest pain (four [15%] p

60 thological fracture (five [3%] vs two [1%]), dyspnoea (four [2%] vs one [1%]), bone pain (one [1%] vs

61 erse events were reported by seven patients: dyspnoea, headache, hypertension, intervertebral disc pr

62 eased neutrophil count (four [2%]), anaemia, dyspnoea, hyponatraemia, increased alanine aminotransfer

63 Dyspnoea improved with relaxin 30 microg/kg compared wit

64 oportion of patients with moderate or marked dyspnoea improvement measured by Likert scale during the

65 The primary endpoints evaluating dyspnoea improvement were change from baseline in the vi

66 Dyspnoea in chronic obstructive pulmonary disease (COPD)

67 ygen therapy is widely used for treatment of dyspnoea in individuals with life-limiting illness who a

68 symptomatic benefit for relief of refractory dyspnoea in patients with life-limiting illness compared

69 atients (54%); fatigue in 23 patients (50%); dyspnoea in ten patients (22%); and stomatitis in three

70 n of the composite of cough, chest pain, and dyspnoea in the QLQ-LC13.

71 related reaction (in four [2%] patients) and dyspnoea (in two [1%]) occurring in more than one patien

72 mpared with placebo were anxiety, dizziness, dyspnoea, increased alanine aminotransferase, influenza,

73 Patients given bosentan had a reduced Borg dyspnoea index and an improved WHO functional class.

74 anges in cardiopulmonary haemodynamics, Borg dyspnoea index, WHO functional class, and withdrawal due

75 aspiration (n=1), rectal haemorrhage (n=1), dyspnoea (n=1), failure to thrive (n=1), and interstitia

76 (n=16 [15%]), thrombocytopenia (n=12 [11%]), dyspnoea (n=3 [3%]), and hypotension (n=3 [3%]) in the B

77 Common symptoms included dyspnoea (n=513 [84%]), cough (n=500 [81%]), and wheezin

78 association with asthma severity (report of dyspnoea, night-time symptoms, rescue medication use, an

79 DRB2 gene significantly associated with less dyspnoea (odds ratio (OR) 0.2, 95% confidence interval (

80 metinib group vs none in the placebo group), dyspnoea (one [2%] of 44 patients in the selumetinib gro

81 vents (three [10%] chest wall pain, two [6%] dyspnoea or cough, and one [3%] fatigue and rib fracture

82 Most individuals present with dyspnoea or evidence of right heart failure.

83 n organ toxicity was pulmonary (grade 3 or 4 dyspnoea or hypoxia including mechanical ventilation), a

84 ne symptom of COPD (cough, sputum, wheezing, dyspnoea, or chest tightness), with at least one of the

85 e pain (ten [9%]), rash (eight [7%]), cough, dyspnoea, or other pulmonary symptoms (five [5%]), fatig

86 r time to deterioration of cough (p<0.0001), dyspnoea (p=0.049), and pain (p=0.041).

87 ed interstitial lung disease meeting defined dyspnoea, pulmonary function, and high-resolution CT (HR

88 t failure with serelaxin was associated with dyspnoea relief and improvement in other clinical outcom

89 t failure with serelaxin was associated with dyspnoea relief and improvement in other clinical outcom

90 erelaxin-treated patients would have greater dyspnoea relief compared with patients treated with stan

91 ing breathlessness (Medical Research Council dyspnoea scale >/=4) to receive active or placebo NMES,

92 the modified Medical Research Council (mMRC) dyspnoea scale (score 0-1 vs >/=2) and the St George's R

93 d beta for Modified Medical Research Council Dyspnoea Scale 0.12 [95% CI 0.00 to 0.24]; p=0.05), lowe

94 ter on the modified Medical Research Council dyspnoea scale.

95 <450 m), and substantial breathlessness (MRC dyspnoea score >/=3).

96 ase in the modified Medical Research Council dyspnoea score from baseline.

97 .81 (SD 0.78), mean Medical Research Council dyspnoea score was 1.33 (SD 0.65); 28 (30%) of 95 patien

98 etic peptide (NT-proBNP)concentrations, Borg dyspnoea score, health-related quality of life (EQ-5D sc

99 partate aminotransferase (six [2%] vs none), dyspnoea (six [2%] vs one [1%]), and pleural effusion (s

100 reported in at least 5% of all patients were dyspnoea (ten [7%]), pneumonia (nine [7%]), and hypoxia

101 ring in more than five patients (>/=3%) were dyspnoea (ten patients [5%]), pneumonia (nine [5%]), and

102 mab group vs two [1%] in the placebo group), dyspnoea (three [1%] vs two [1%]); respiratory failure (

103 %] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (

104 six (7%) were deemed treatment related, with dyspnoea (three [3%]) and pneumonia (two [2%]) reported

105 [8%] of 92 patients), rash (four [4%]), and dyspnoea (three [3%]).

106 , oedema (four [8%] and none, respectively), dyspnoea (three [6%] and two [10%], respectively), and h

107 her toxic effects were fatigue (11 vs 9) and dyspnoea (three vs four).

108 which symptomatic treatment does not control dyspnoea to the patient's satisfaction, sedation is an e

109 rombocytopenia, abdominal pain, anxiety, and dyspnoea (two [5%] each).

110 fatigue, asthenia, atrial fibrillation, and dyspnoea (two [5%] each); in the placebo group, such eve

111 on; headache/visual disturbances; chest pain/dyspnoea; vaginal bleeding with abdominal pain; systolic

112 ptoms (cough, chest pain, sputum production, dyspnoea) with no worsening in any symptom at 72 h after